Title: MERIT – MEtformin for treating PAD Related walking Impairment Trial Partnership
Status: Seed funding
Summary: This is a placebo-controlled randomised trial performed across multiple Aisytralian sites. Participants with intermittent claudication, but no diabetes, will be randomised to metformin or placebo daily and followed for six months. The primary outcome is the change in six-minute walk test (6MWT) distance over six months.
Chief Investigator: Prof John Golledge – email@example.com
For more information contact: Alkira Vann, Clinical Trials Coordinator – firstname.lastname@example.org
Title: IDEAL Partnership – Improved cardiovascular Disease hEALth service delivery in Australia
Summary: The IDEAL study aims to improve the way doctors manage patients’ risk of cardiovascular disease, including conditions such as heart attack or stroke. This research focuses on the development of a new service to calculate cardiovascular risk and deliver this information to GPs to help them make well-informed treatment decisions around risk management to improve outcomes for their patients.
Chief Investigator: Prof James Sharman – email@example.com
For more information contact: Gudrun Wells – firstname.lastname@example.org
Title: Metformin Aneurysm Trial
Summary: Metformin Aneurysm Trial is a multicentre, randomised, placebo-controlled trial to assess if 1500 mg of metformin per day will reduce Abdominal Aortic Aneurysm (AAA)-related events in patients with small AAAs who do not have diabetes.
Chief Investigator: Prof Jon Golledge – email@example.com
For more information contact: Sophie Rowbotham, Global Trial Manager – firstname.lastname@example.org